Labcorp Holdings Earnings Call Transcripts
Fiscal Year 2026
-
The meeting covered strong 2025 financial results, board elections, executive compensation, and auditor ratification, with all proposals passing by wide margins. Management addressed regulatory risks in animal research supply chains and affirmed operational resilience.
-
Q1 2026 delivered 5.8% revenue growth, 10.6% EPS growth, and margin expansion, driven by strong Diagnostics and BLS performance, specialty testing, and strategic partnerships. Guidance for 2026 was raised, with continued focus on innovation, M&A, and operational efficiency.
-
Key growth in 2025 was driven by specialty testing, hospital acquisitions, and successful integration of Invitae, leading to new cancer diagnostics. AI and automation are enhancing efficiency, while strong payer relationships and disciplined M&A support future growth. PAMA and Results legislation remain key regulatory variables.
Fiscal Year 2025
-
Delivered strong 2025 results with 7% revenue and 13% adjusted EPS growth, driven by Diagnostics and Central Labs. 2026 guidance calls for 5.4% revenue growth at midpoint, 9% adjusted EPS growth, and margin expansion, supported by robust specialty testing and acquisitions.
-
Q3 2025 saw strong revenue and margin growth, with diagnostics and central labs driving performance. Guidance for 2025 was raised for EPS and free cash flow, while strategic acquisitions and innovation in specialty testing supported growth. PAMA and early development delays remain key risks.
-
Strong growth in diagnostics and biopharma is driven by organic volume, innovation, and hospital partnerships. Margins are expanding due to cost initiatives and the Invitae acquisition, while payer relationships and the deal pipeline remain robust. Regulatory and policy changes are being managed proactively.
-
Q2 2025 saw 10% revenue growth and margin expansion, with strong performance in both diagnostics and BLS segments. Full-year guidance for revenue, EPS, and free cash flow was raised, reflecting robust demand, successful acquisitions, and operational efficiencies.
-
The meeting covered strong 2024 performance, board and executive updates, and five key proposals, all of which passed with overwhelming shareholder support. Management addressed biosafety risks in research animal operations and detailed risk mitigation efforts.
-
Q1 2025 saw 5.3% revenue growth, strong diagnostics and BLS performance, and 4% higher adjusted EPS. Guidance for revenue, margins, and free cash flow was reaffirmed, with EPS midpoint raised. Strategic acquisitions, new test launches, and technology innovation support continued growth.
-
Diagnostics and Central Laboratory businesses showed strong growth in 2024, with momentum expected to continue into 2025. Regulatory changes, strategic acquisitions, and a focus on four core therapeutic areas underpin growth, while capital allocation remains balanced.
Fiscal Year 2024
-
Q4 revenue rose 9.8% to $3.3B, with strong growth in both diagnostics and biopharma. 2025 guidance projects 6.7%-8% revenue growth, margin expansion, and adjusted EPS of $15.60-$16.40. Acquisitions, innovation, and cost savings initiatives support continued growth.
-
Q3 2024 saw 7% revenue growth, strong Diagnostics and Central Labs performance, and continued margin headwinds from Invitae and weather. Guidance for 2024 remains robust, with Early Development expected to return to growth and inorganic growth outlook raised.
-
Recent hospital and regional lab deals are accelerating inorganic growth, with stable core diagnostics and central lab businesses driving strong margins and outlook. The Invitae acquisition is on track for accretion in 2025, and early development is expected to return to growth by year-end.
-
Second quarter revenue grew 6% year-over-year to $3.2 billion, with strong diagnostics and central lab performance offsetting early development declines. 2024 guidance was raised for revenue but lowered for EPS due to Invitae dilution, which is expected to be accretive in 2025.
-
The company outlined robust growth strategies across diagnostics and biopharma services, emphasizing specialty testing, global expansion, and accretive acquisitions. 2024 guidance was raised following strong Q1 results, with long-term targets of 5–8% revenue growth and margin expansion.